Chance (adjusted OR) of patients of different age groups with CHD receiving different secondary preventive treatments at 31 March of successive years
| Year | Age group (years) | |||||||
|---|---|---|---|---|---|---|---|---|
| <55* | 55–64 | 65–74 | ⩾75 | |||||
| Received treatment | Received treatment | Adjusted OR (95% CI)† | Received treatment | Adjusted OR (95% CI)† | Received treatment | Adjusted OR (95% CI)† | ||
| *Reference group; †adjusted for sex, practice differences, deprivation, and number of co-morbidities. | ||||||||
| ACE inhibitors | ||||||||
| 1997 | 79 (11.6%) | 168 (12.9%) | 0.9 (0.7 to 1.2) | 210 (13.3%) | 0.9 (0.7 to 1.2) | 147 (12.0%) | 0.8 (0.6 to 1.1) | |
| 1998 | 143 (13.8%) | 291 (15.8%) | 0.9 (0.8 to 1.2) | 377 (17.0%) | 1.0 (0.8 to 1.2) | 296 (18.0%) | 1.1 (0.9 to 1.4) | |
| 1999 | 234 (17.3%) | 454 (18.3%) | 0.9 (0.7 to 1.1) | 636 (20.5%) | 0.9 (0.8 to 1.1) | 507 (21.0%) | 1.0 (0.8 to 1.2) | |
| 2000 | 285 (20.1%) | 595 (22.0%) | 1.0 (0.8 to 1.2) | 898 (24.1%) | 1.0 (0.8 to 1.1) | 804 (24.8%) | 1.0 (0.8 to 1.1) | |
| 2001 | 439 (26.0%) | 850 (27.0%) | 0.9 (0.8 to 1.1) | 1303 (29.3%) | 0.9 (0.8 to 1.0) | 1082 (27.2%) | 0.8 (0.7 to 0.9) | |
| 2002 | 541 (30.0%) | 1100 (32.6%) | 1.0 (0.9 to 1.1) | 1636 (34.2%) | 1.0 (0.8 to 1.1) | 1427 (31.9%) | 0.8 (0.7 to 0.9) | |
| Antiplatelets | ||||||||
| 1997 | 234 (34.3%) | 426 (32.7%) | 0.9 (0.8 to 1.1) | 584 (36.9%) | 1.2 (1.0 to 1.4) | 386 (31.4%) | 0.9 (0.8 to 1.1) | |
| 1998 | 465 (44.9%) | 922 (50.1%) | 1.2 (1.1 to 1.5) | 1176 (53.0%) | 1.5 (1.3 to 1.7) | 783 (47.6%) | 1.2 (1.0 to 1.4) | |
| 1999 | 685 (50.7%) | 1539 (61.9%) | 1.6 (1.4 to 1.8) | 2013 (64.8%) | 1.9 (1.6 to 2.2) | 1455 (60.3%) | 1.6 (1.4 to 1.9) | |
| 2000 | 796 (56.2%) | 1864 (68.8%) | 1.7 (1.5 to 1.9) | 2774 (74.3%) | 2.2 (1.9 to 2.5) | 2243 (69.3%) | 1.8 (1.5 to 2.0) | |
| 2001 | 956 (56.7%) | 2163 (68.6%) | 1.7 (1.5 to 1.9) | 3326 (74.9%) | 2.3 (2.0 to 2.6) | 2744 (68.9%) | 1.7 (1.5 to 1.9) | |
| 2002 | 1057 (58.6%) | 2376 (70.4%) | 1.6 (1.5 to 1.9) | 3652 (76.4%) | 2.3 (2.0 to 2.6) | 3221 (72.0%) | 1.8 (1.6 to 2.0) | |
| β Blockers | ||||||||
| 1997 | 201 (29.5%) | 362 (27.8%) | 0.9 (0.7 to 1.1) | 342 (21.6%) | 0.6 (0.5 to 0.8) | 195 (15.9%) | 0.4 (0.3 to 0.5) | |
| 1998 | 410 (39.6%) | 684 (37.2%) | 0.9 (0.8 to 1.0) | 645 (29.1%) | 0.6 (0.5 to 0.7) | 364 (22.1%) | 0.4 (0.3 to 0.5) | |
| 1999 | 619 (45.8%) | 1096 (44.1%) | 0.9 (0.8 to 1.0) | 1171 (37.7%) | 0.7 (0.6 to 0.8) | 659 (27.3%) | 0.4 (0.4 to 0.5) | |
| 2000 | 727 (51.3%) | 1346 (49.7%) | 0.9 (0.8 to 1.0) | 1623 (43.5%) | 0.7 (0.6 to 0.8) | 1103 (34.1%) | 0.5 (0.4 to 0.5) | |
| 2001 | 916 (54.3%) | 1641 (52.0%) | 0.9 (0.8 to 1.0) | 2070 (46.6%) | 0.7 (0.6 to 0.8) | 1459 (36.6%) | 0.5 (0.4 to 0.5) | |
| 2002 | 988 (54.8%) | 1835 (54.4%) | 1.0 (0.9 to 1.1) | 2329 (48.7%) | 0.7 (0.7 to 0.8) | 1742 (38.9%) | 0.5 (0.4 to 0.6) | |
| Statins | ||||||||
| 1997 | 152 (22.2%) | 261 (20.1%) | 0.9 (0.7 to 1.1) | 211 (13.3%) | 0.5 (0.4 to 0.6) | 42 (3.4%) | 0.1 (0.1 to 0.2) | |
| 1998 | 358 (34.6%) | 554 (30.1%) | 0.9 (0.7 to 1.1) | 507 (22.9%) | 0.5 (0.4 to 0.6) | 101 (6.1%) | 0.1 (0.1 to 0.1) | |
| 1999 | 571 (42.2%) | 1030 (41.4%) | 1.0 (0.8 to 1.1) | 1039 (33.4%) | 0.7 (0.6 to 0.7) | 259 (10.7%) | 0.1 (0.1 to 0.2) | |
| 2000 | 752 (53.1%) | 1455 (53.7%) | 1.0 (0.9 to 1.2) | 1818 (48.7%) | 0.8 (0.7 to 0.9) | 558 (17.2%) | 0.2 (0.2 to 0.2) | |
| 2001 | 881 (52.3%) | 1699 (53.9%) | 1.1 (0.9 to 1.2) | 2149 (48.4%) | 0.8 (0.7 to 0.9) | 856 (21.5%) | 0.2 (0.2 to 0.3) | |
| 2002 | 1013 (56.2%) | 2064 (61.2%) | 1.2 (1.1 to 1.4) | 2862 (59.1%) | 1.1 (1.0 to 1.2) | 1364 (30.5%) | 0.3 (0.3 to 0.4) | |
| At least one secondary preventive treatment | ||||||||
| 1997 | 442 (64.8%) | 868 (66.7%) | 1.0 (0.8 to 1.2) | 1031 (65.1%) | 0.9 (0.7 to 1.1) | 710 (57.8%) | 0.6 (0.5 to 0.7) | |
| 1998 | 774 (69.6%) | 1462 (74.3%) | 1.2 (1.0 to 1.5) | 1728 (72.1%) | 1.1 (0.9 to 1.3) | 1183 (64.3%) | 0.7 (0.6 to 0.9) | |
| 1999 | 1054 (74.3%) | 2143 (82.2%) | 1.5 (1.3 to 1.8) | 2691 (81.9%) | 1.5 (1.3 to 1.7) | 1958 (74.8%) | 1.0 (0.9 to 1.2) | |
| 2000 | 1153 (77.5%) | 2465 (86.2%) | 1.7 (1.4 to 2.0) | 3991 (87.5%) | 1.9 (1.6 to 2.2) | 3394 (80.1%) | 1.1 (1.0 to 1.4) | |
| 2001 | 1347 (79.4%) | 2869 (88.4%) | 1.9 (1.6 to 2.3) | 4089 (89.5%) | 2.0 (1.7 to 2.4) | 3497 (83.3%) | 1.2 (1.0 to 1.4) | |
| 2002 | 1488 (80.3%) | 3461 (89.3%) | 2.0 (1.7 to 2.3) | 4915 (91.3%) | 2.4 (2.0 to 2.8) | 4551 (85.5%) | 1.3 (1.1 to 1.5) | |